South Korea’s Celltrion has joined the many pharma companies fighting the COVID-19 coronavirus outbreak, saying it is working on an antibody-based antiviral and a self-testing diagnosis kit providing results within 15-20 minutes. Best known as a manufacturer of biosimilars –…
Roche Launches Phase III Study of Rheumatoid Arthritis Drug for COVID-19 Pneumonia
Days after Swiss pharma giant Roche began shipping hundreds of thousands of its recently-approved COVID-19 test to laboratories in the United States, the company has initiated a late-stage trial assessing its rheumatoid arthritis drug Actemra in patients who have severe…
Pfizer Posts Positive Results in Two Phase III Studies, Postpones Investor Day
Pfizer had a good day Wednesday with the announcement of positive results from two Phase III trials, one in moderate to severe atopic dermatitis and one in pneumococcal disease. In pneumococcal disease, Pfizer announced top-line results from a late-stage study…
BioXcel Therapeutics Provides an Update on its Ongoing Phase 3 SERENITY Trials
More than one-third of the SERENITY I & II patients have been dosed, including over 100 bipolar patients On track to report topline data from both studies in mid-2020 NEW HAVEN, Conn., March 19, 2020 (GLOBE NEWSWIRE) — BioXcel Therapeutics,…
DePuy announces CE mark for dual mobility system for hips
Johnson & Johnson has announced that DePuy Synthes, which produces cementless hip implants, has been informed of the European CE mark on its new Bi-Mentum Dual Mobility System for use in patients with a higher risk of dislocation. Bi-Mentum features a standard…
Market for 5G in manufacturing expected to reach $10.8bn by 2030
The market for 5G cellular connections in manufacturing is expected to reach $10.8 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 187%, according to global tech market advisory firm, ABI Research. The current Industry 4.0 digitalisation discourse…
Cortexyme Announces Gain Trial in Alzheimer’s Disease Has Reached Enrollment Milestone of 300 Patients
– Sub-study shows greater than 90% of enrolled patients have moderate to severe periodontal disease, indicating relevance to mechanism of action against P. gingivalis – Interim analysis of the Phase 2/3 GAIN Trial expected to occur before year-end 2020 …
Sanofi and Regeneron begin global Kevzara® (sarilumab) clinical trial program in patients with severe COVID-19
CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 16, 2020 /PRNewswire/ — Sanofi and Regeneron Pharmaceuticals, Inc. today announced they have started a clinical program evaluating Kevzara® (sarilumab) in patients hospitalized with severe COVID-19. Kevzara is a fully-human monoclonal antibody that inhibits the…
Novo Nordisk Pauses Three Clinical Trials Because of Non-Fatal Thrombotic Events
Denmark’s Novo Nordisk paused three clinical trials of concizumab over safety issues. The trials are evaluating the drug for hemophilia A and B. No more patients will be enrolled in the trials and current treatment “will cease” while they determine…
FDA gives Lilly’s Olumiant breakthrough status for hair loss
Eli Lilly’s Olumiant is facing tough competition in its approved rheumatoid arthritis indication, but could take the lead in alopecia areata (AA), a common cause of hair loss. The FDA has granted Lilly a breakthrough designation (BTD) for JAK inhibitor…
